Selection bias, investment decisions and treatment effect distributions
When making decisions regarding the investment and design for a Phase 3 programme in the development of a new drug, the results from preceding Phase 2 trials are an important source of information. However, only projects in which the Phase 2 results show promising treatment effects will typically be...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
John Wiley and Sons Ltd
2021
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |